

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

Estimates of TB burden^a 2012

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	25 (12–44)	48 (23–84)
Mortality (HIV+TB only)	4.6 (3.8–5.3)	8.8 (7.3–10)
Prevalence (includes HIV+TB)	260 (200–320)	489 (377–616)
Incidence (includes HIV+TB)	200 (170–230)	377 (322–435)
Incidence (HIV+TB only)	19 (16–21)	35 (30–41)
Case detection, all forms (%)	71 (62–83)	

TB case notifications 2012

NEW CASES (%)	RETREATMENT CASES (%)
Smear-positive 42 909 (31)	Relapse 4 558 (40)
Smear-negative 73 042 (53)	Treatment after failure 1 671 (14)
Smear-unknown / not done 0 (0)	Treatment after default 521 (5)
Extrapulmonary 20 661 (15)	Other 4 787 (41)
Other 0 (0)	
Total new 136 612	Total retreatment 11 537
Other (history unknown) 0	
Total new and relapse 141 170	Total cases notified 148 149

New cases

	SMEAR-POSITIVE	SMEAR-NEGATIVE/ UNKNOWN/ NOT DONE	EXTRAPULMONARY
M:F ratio	1.9		
Age < 15	338		

Laboratories

Smear (per 100 000 population)	0.9
Culture (per 5 million population)	0.2
Drug susceptibility testing (per 5 million population)	0.2
Is second-line drug susceptibility testing available?	Yes, in and outside country

Treatment success rate 2011 (%)

New smear-positive and/or culture-positive	86
New smear-negative/extrapulmonary	90
Retreatment	72
Is rifampicin used throughout treatment for new patients?	Yes

TB/HIV 2012

	NUMBER	(%)
TB patients with known HIV status	19 219	(13)
HIV-positive TB patients	5 161	(27)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	4 270	(83)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Estimates of MDR-TB burden 2012^a

	NEW	RETREATMENT
% of TB cases with MDR-TB	4.2 (3.1–5.6)	10 (6.9–14)
MDR-TB cases among notified pulmonary TB cases	4 900 (3 600–6 500)	1 200 (790–1 600)

Reported cases of MDR-TB 2012

	NEW	RETREATMENT	TOTAL
Cases tested for MDR-TB			
Laboratory-confirmed MDR-TB cases			778
Patients started on MDR-TB treatment			442

Financing TB control

National TB programme budget (US\$ millions)	36
% Funded domestically	2%
% Funded internationally	39%
% Unfunded	60%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

^a Ranges represent uncertainty intervals.

